Information Provided By:
Fly News Breaks for August 7, 2019
HAE
Aug 7, 2019 | 08:00 EDT
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $165 from $140 saying the company's fiscal Q1 results reinforced his core thesis. The company offers "significant" earnings upside potential in the years ahead on a combo of Plasma volumes, NexSys benefits, and cost savings, Petrone tells investors in a research note. He believes "things trending in the right direction" for Haemonetics and keeps a Buy rating on the shares. The analyst's upside case is now $200 per share, up from $175.
News For HAE From the Last 2 Days
There are no results for your query HAE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.